BMRN — BioMarin Pharmaceutical Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $58.51
- YTD price return
- -1.55%
- YTD total return
- -1.55%
- Market cap
- 11.3B
- Enterprise value
- 14.8B
- Shares outstanding
- 193.7M
- 52W low
- $49.26
- 52W high
- $70.98
- From 52W high
- -17.57%
- From 52W low
- +18.78%
- 52W range
- 43%$49.26–$70.98
- Beta
- 0.23
Volume
- Rel volume
- 0.92×
- 30D volume
- 2.4M
- 30D $ vol
- 137.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$1.2M
- Insider net 1Y
- −$4.3M
Form 4 transactions by trade date, as filed; latest on file 2026-09-02.
Fundamentals
- Sales (ttm)
- 3.7B
- Sales/share
- $18.87
- EPS (ttm)
- -$0.10
- FCF (ttm)
- 557.9M
- FCF/share
- $2.88
- Book value/share
- $32.30
- Net margin
- -0.52%
- ROE
- -0.31%
- ROA
- -0.17%
- Debt / equity
- 0.56×
- Current ratio
- 2.44
Growth (CAGR, ttm) · 10Y
- Sales
- +18.15%+16.51%+14.61%+13.34%
- FCF
- -32.98%+151.37%+25.10%n/a
- Shares
- +0.82%+0.93%+1.08%+1.20%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +17.18%+15.44%+13.39%+12.00%
- FCF/share
- -33.53%+149.05%+23.77%n/a
- Book value/share
- +2.45%+7.50%+6.81%+7.70%
- Price
- +7.44%-12.56%-6.24%-4.15%
- Total return
- +7.44%-12.56%-6.24%-4.15%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -600.4×
- P/OI (ttm)
- 99.5×
- Fwd P/E
- 9.0×
- P/S (ttm)
- 3.1×
- P/B (mrq)
- 1.8×
- P/FCF (ttm)
- 20.3×
- EV/EBITDA (fy)
- 39.1×
- EV/Sales (ttm)
- 4.1×
- FCF yield (ttm)
- 4.92%
- Buyback yield (realized, 1y)
- -0.82%
- Shareholder yield (realized, 1y)
- -0.82%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/E
- 69th
- P/OI
- 62nd
- P/S
- 2nd
- P/B
- 8th
- P/FCF
- 28th
Bar = where today’s multiple sits in BMRN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y CAGR −16.7%10Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY −53.0%TTM: operating cash flow $676.6M, capex −$118.8M
Q3 2026: operating cash flow $188.2M, capex −$28.3M
Shares (diluted)
5Y +3.0%10Y +23.4%YoY +0.8%Net income
5Y CAGR −16.4%10Y n/mYoY n/mAbout BioMarin Pharmaceutical#
Data provided bySource: Twelve DataBioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.
San Rafael, CA·3,221 employees·Biotechnology·biomarin.com·As of Oct 28, 2026
Recent filings#
- Nov 2Earnings · Earnings release — EPS $0.02 vs −$0.30 est. (+106.7%); revenue $1.02B (+32% y/y) 3.1%
- Oct 68-K · Results of operations
- Sep 2Insider sale · Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares for $1.2M at $66.28
- Aug 318-K · BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
- Aug 188-K · BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s Pipeline
ETFs holding BMRN#
22 of the 193 ETFs ChartRow carries live hold BMRN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 0.9% |
| IBB | iShares Biotechnology ETF | 0.8% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
